InvestorsHub Logo
Followers 144
Posts 8676
Boards Moderated 0
Alias Born 10/07/2013

Re: MedResCollab post# 200769

Wednesday, 07/10/2019 10:45:55 AM

Wednesday, July 10, 2019 10:45:55 AM

Post# of 424147
M-

Once again, you must present counter-evidence to our current arguments regarding Amarin Corp., including our evidence the REDUCE-IT results are confounded, and FDA will likely not approve the efficacy supplement without supplementary data proving mineral oil has no effect on multiple cardiac medications, and also our evidence that the patents covering Vascepa are all either invalidated for lacking novelty and/or for obviousness, or are otherwise not infringed by ANDA filers.

First of all you did not provide any evidence … just your view / interpretation of available info.

The counter-arguments will be the real evidences as:
- no AdCom
- FDA approval
- settlement with ANDAs or the favorable court decision

If all these in the bags: will you think you were wrong or it will means everybody were wrong and ignored the "evidences" provided by you? ...

Best,
G

"There are some things money can't buy. For everything else, there's AMRN."

Disclosure: I am long with this stock. I wrote this post myself, and it expresses my own opinions (IMHO). I am not receiving compensation for

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News